Buying Cialis Europe

Class: Phosphodiesterase Type 5 Inhibitors VA Class: GU900 Chemical Name: (6R,12aR) - 6 - (1,3 - benzodioxol - 5 - yl) - 2,3,6,7,12,12a - hexahydro - 2 - methylpyrazino[1′,2′:1,6]pyrido[3,4 - b]indole - 1,4 - dione Molecular Formula: C₂₂H₁₉N₃O₄ CAS Number: 171596-29-5

Vasodilating agent; a selective phosphodiesterase (PDE) type 5 inhibitor.

Male impotence

To facilitate attainment of your sexually functional erection in males with impotence (ED, impotence). Can be utilized when needed (at the moment) or each day (without regard to timing of sexual acts). Some experts recommend a selective PDE type 5 inhibitor as first-line therapy for ED unless contraindicated. Evidence currently insufficient to guide superiority of merely one selective PDE type 5 inhibitor over another. Symptomatic management (e.g., to enhance lower urinary tract symptoms) of BPH (BPH, benign prostatic hypertrophy). Not recommended to be used in conjunction with an α-adrenergic blocking agent (e.g., doxazosin, terazosin); inadequate data and prospects for additive hypotensive effects. (See Concomitant Administration with α-Adrenergic Blocking Agents under Cautions.) Remedy for both ED and symptomatic BPH in males with such coexisting conditions. Symptomatic management (i.e., to improve exercise capacity) of patients with pulmonary arterial hypertension (PAH; World Health Organization [WHO] group I pulmonary hypertension). Efficacy established principally in patients with NYHA functional class II–III PAH (idiopathic or familial PAH or PAH connected with connective tissue disease). Recommended by ACC and also other experts as one of several options for management of PAH in patients with NYHA functional class II or early class III symptoms who're not candidates for calcium-channel blocker therapy or even in whom such therapy failed. When deciding on the ideal regimen, consider factors for instance disease severity, route of administration, potential negative effects, patient preference, and clinician experience. Has been utilized in conjunction with other PAH therapies (e.g., endothelin-receptor antagonists, prostanoids). Could possibly be considered in patients that do not respond adequately to initial monotherapy; however, additional studies was required to establish optimal drug combinations.